TRK-IN-31
TRK-IN-31 is an orally active TRK inhibitor with an IC50 of 1.8 nM. TRK-IN-31 has superior antiproliferative activity in the Ba/F3-MPRIP-TRKAG667C cells, and potently inhibits TRK kinase activity with high selectivity. TRK-IN-31 significantly inhibits tumor growth in Ba/F3-MPRIP-TRKAG667C subcutaneous tumor mice model[1].
Product Specifications
UNSPSC
12352005
Target
Trk Receptor
Related Pathways
Neuronal Signaling; Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Smiles
FC1=CC=C(C=C1[C@@H]2N(C3=CNC(C(C(NC4=CC5=C(C=C4)OC(C(N6CCN(CC6)C)=O)=C5)=O)=C3)=O)CCC2)F
Molecular Formula
C30H29F2N5O4
Molecular Weight
561.58
References & Citations
[1]Xu Z, et al. Structural Optimization of Next-Generation TRK Inhibitors against Acquired Drug Resistance Mutations for the Treatment of Solid Tumors. J Med Chem. 2025 Jun 12; 68 (11) :11484-11501.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
Trk
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
PK54020M9-01 50 µg
CD8A & CD8B Heterodimer Protein, Cynomolgus, Recombinant (Flag & His Tag)
Ask
View Details PK54020M9-02 1 mg
CD8A & CD8B Heterodimer Protein, Cynomolgus, Recombinant (Flag & His Tag)
Ask
View Details 
054575-01 10 µg
Tumor Necrosis Factor Receptor Superfamily, Member 1B (TNFRSF1B), Recombinant, Rat, His-Tag
Ask
View Details